

Rotavirus epidemic & its vaccination

E. Shim¹, C. Castillo-Chavez¹, H.T. Banks²,
Z. Feng³ and M. Martcheva⁴


¹Arizona State University

²North Carolina State University

³Purdue University

⁴University of Florida


Goals



- Study seasonality of annual epidemics: Compare two types of vaccines
- Set up an age-structure epidemic model of rotavirus epidemic
- Numerical implementation of an age-structure model.
- Immunological issues: Passive immunity and vaccine

Morphology of rotavirus

- Family Reoviridae
- Wheel-like distinct appearance under EM (Latin, "rota"=wheel)
- 70-85 nm diameter
- Non-enveloped, double-shelled viruses




(Picture Source: <http://www.sourcemolecular.com/virus2.jpg>)

Epidemiology (1)

- 95% of children worldwide are infected by 3-5 years of age.
- 80% of population have antibody against rotavirus by age 3.
- More frequent in Winter.
- Patterns : annual epidemics occurring from November to April.
(starting from South western area in November to North east)
- Incidence peaks among children ages 4 to 36 months.
- Symptom : vomiting, diarrhea, dehydration.
(Repeat infection may occur with milder symptoms)

Epidemiology (2)

- Latent periods: 24–48 hr.
- Infectious period: 3–7 days.
- Asymptomatic infections are common in adults and older children.
- Primary transmission mode is fecal-oral.
- Ingestion of contaminated food or water and contact with contaminated surfaces




Replication

- Attached to cell receptors contained sialic acid
- Internalized and uncoated via endolysosomes
- Early transcription by viral RNA polymerase occurs inside sub-viral particle
- Resulted in synthesis of (+) mRNAs and are translated in the cytoplasm.
- Reassortment occurs during Early transcription.
- Secondary transcription occurs in cytoplasm in later infection in a conservative fashion.
- Uncapped non-polyadenylated transcripts
- Particles assemble in the cytoplasm 6-7 h after infection
- Budding from the E.R. into internal spaces & are eventually released when the cell lyses.

Pathogenesis

- infect upper two-third of duodenal epithelial cell
- infectious particles are released to intestinal lumen and undergo further replication in distal areas
- death of over 600,000 children annually worldwide




(Picture Source: www.eur.nl/fgg/kgk/gastro/rotavirus.gif)

History of Rotavirus vaccine

- Aug 1998: FDA approved Rotashield™, the 1st rotavirus vaccine
- Sep 1998 - July 1998: 15 cases of intussusception cases in were reported to VAERS.
- Sep 1998 - July 1999: CDC reports preliminary data associating Rotashield™ with intussusception and recommends postponing use.
- Oct 1999: Rotashield™ was withdrawn from the market.
- July 2004: Mexican board of Health approved the use in Mexico of Rotarix™ - GlaxoSimthKlein's new rotavirus vaccine.

Number of rotavirus positive specimen Australia, 1993-1996




Solid line: hospital admission for acute gastroenteritis in children under five years of age

Dashed line: the number of rotavirus-positive specimens received from participating hospitals in that State, rescaled from the hospital to the State level.

(J.B. Carlin et al. *MJA* 1998; 168: 252-256)

Seasonal pattern



M: maternal antibodies class
 S: Susceptibles
 L: Latent
 I: Infectious
 R: Recovered

Important parameters

q : breast feeding rate

$1 - \xi$: protection role of breast milk

ρ : average breast feeding period

where

$$\beta(t) = \beta_0(1 + \beta_1 \cos 2\pi(t - \tau/365))$$

Model with seasonal pattern of infection

$$M' = q\mu N - \xi\beta MI/N - (\rho + \mu)M,$$

$$S' = \mu[(1 - q)N - S] + \rho M - \beta SI/N + \delta R,$$

$$L' = \xi\beta MI/N + \beta SI/N - (\alpha + \mu)I,$$

$$I' = \alpha L - (\mu + \gamma)I$$

$$R' = \gamma I - (\mu + \delta)R$$


where

$$\beta(t) = \beta_0(1 + \beta_1 \cos 2\pi(t - \tau/365))$$

Total population, $N(t) = M+S+L+I+R$

Seasonal pattern of rotavirus infection in Victoria, Australia (1993-1996)

Number of infectives



days

— : simulated

— : data

Data fitting





FIGURE 2. Number of infective people of rotavirus in Victoria, Australia, 1993-1996 ([3]) and the fitted graph using seasonality model using various fixed reduction in infection rate due to maternal antibodies. ξ values used: 0.2, 0.3, 0.4 and 0.5.

Estimated parameter values for fitting (using data set in Victoria, Australia, 1993–1996)

TABLE 1. Confidence intervals of estimated parameters when $\xi = 0.2, 0.3, 0.4$ and 0.5 respectively

parameters	best-fit values	standard error	95% confidence intervals
ρ	0.0003	0.0000	[0.0003, 0.0003]
	0.0001	0.0000	[0.0001, 0.0001]
	0.0000	0.0000	[0.0000, 0.0000]
	0.0000	0.0000	[0.0000, 0.0000]
β_0	0.2077	0.0000	[0.2077, 0.2077]
	0.2073	0.0000	[0.2073, 0.2073]
	0.2099	0.0000	[0.2099, 0.2099]
	0.2070	0.0000	[0.2070, 0.2070]
β_1	0.2217	0.0300	[0.1629, 0.2805]
	0.2235	0.0300	[0.1647, 0.2823]
	0.2266	0.0316	[0.1646, 0.2886]
	0.2353	0.0332	[0.1703, 0.3003]
δ	0.1000	0.0436	[0.0146, 0.1854]
	0.1000	0.0447	[0.0123, 0.1877]
	0.1000	0.0447	[0.0123, 0.1877]
	0.1000	0.0469	[0.0081, 0.1919]
γ	0.2028	0.0000	[0.2028, 0.2028]
	0.2026	0.0000	[0.2026, 0.2026]
	0.2055	0.0000	[0.2055, 0.2055]
	0.2032	0.0000	[0.2032, 0.2032]
τ	145.6292	3.5942	[138.5846, 152.6738]
	145.8228	3.5768	[138.8123, 152.8333]
	145.7564	3.5411	[138.8159, 152.6969]
	145.4982	3.5180	[138.6030, 152.3934]

Model including “two types” of vaccines model



λ : neonatal vaccination
 ϕ : post – birth vaccination

$$M' = q\mu N - \xi\beta MI/N - (\rho + \mu)M,$$

$$S' = \mu[(1 - \lambda)(1 - q)N - S] - \beta SI/N - \phi S + \rho M + \delta R + \varepsilon V,$$

$$L' = \xi\beta MI/N + \beta SI/N - (\alpha + \mu)L,$$

$$I' = \alpha L - (\gamma + \mu)I,$$

$$R' = \gamma I - (\delta + \mu)R,$$

$$V' = \lambda(1 - q)\mu N + \phi S - (\varepsilon + \mu)V$$

with

$$N = M + S + L + I + R + V$$

$$\beta = \beta_0 [1 + \beta_1 \cos(2\pi(t - \tau))]$$

Ref: [2] (By E.Shim, H. T.Banks and C. Castillo-Chavez)

Simulated results: comparing effects of two vaccines.

Neonatal vaccine VS Post-birth vaccine





FIGURE 7. Simulated results with various after-birth vaccination rates ($\phi = 0, 0.3, 0.6, 0.8$). Parameters used: $\epsilon = 0.0001$, $\alpha = 0.5$, $\gamma = 0.2$. ρ , β_0 , β_1 and δ are fixed at best-fit values from Table 1.

Rates (lambda & phi) used: 0.3, 0.6 and 0.8

Reproductive ratios VS neonatal vaccine rates using various breast feeding duration (2,3,4 and 5 months)




FIGURE 5. Reproductive ratio using neonatal vaccination rate (λ) and breast-feeding rate (q) using various breast-feeding durations (two, three, four and five months)

X-axis: neonatal vaccine rate (λ)
Y-axis: breast-feeding rate (q)
Z-axis: reproductive ratio

Reproductive ratios VS post-birth vaccine rates using various breast feeding duration (2,3,4 and 5 months)





FIGURE 6. Reproductive ratio using post-breast feeding vaccination rate (ϕ) and breast-feeding rate (q) using various breast-feeding durations (two, three, four and five months)

X-axis: post-birth vaccine rate (ϕ)
Y-axis: breast-feeding rate (q)
Z-axis: reproductive ratio

Pattern #2: Age distribution of rotavirus cases

Age distribution versus infecting serotype



C. Kirkwood et al. Report of the Australian Rotavirus Surveillance Program
2003-2004 Comm. Dis. Int. Vol 28 No4.


Assumptions


- Population is divided into six groups: breast-fed, susceptible, latent, infective, recovered, and vaccinated.
- All newborns enter either breast-fed or susceptible class and we assume maternal antibody protection against infection.
- Portion of susceptible, $\phi(a)$, is vaccinated but vaccine is incomplete and non-permanent.
- Natural immunity (incomplete and non-permanent) gained from previous infection is assumed.
- Age-dependent mixing : contacts between individuals are driven by age-class activity level and their density.


Parameters

- Λ : recruitment/birth rate.
- $\beta(a)$: age-specific probability of becoming infected.
- $c(a)$: age-specific per-capita contact rate.
- $\mu(a)$: age-specific per-capita mortality rate.
- $\gamma(a)$: age-specific per-capita recovery rate.
- mixing: $p(t,a,a')$ is probability that an individual of age a has contact with an individual of age a' given that it has a contact with a member of the population

Mixing Rules


$$p(t, a, a') \geq 0$$


$$\int_0^{\infty} p(t, a, a') da' = 1$$



$$c(a)p(t, a, a')n(t, a) = c(a')p(t, a', a)n(t, a')$$



Proportionate mixing:

$$p(t, a, a') = p(t, a') = \frac{c(a')n(t, a')}{\int_0^{\infty} c(u)n(t, u)du}$$

Diagram of mathematical model



Age-structured model of rotavirus infection

$$\left(\frac{\partial}{\partial t} + \frac{\partial}{\partial a}\right) X(t, a) = -d(a)X(t, a) - \mu(a)X(t, a)$$

$$\left(\frac{\partial}{\partial t} + \frac{\partial}{\partial a}\right) S(t, a) = d(a)X(t, a) - \beta(a)c(a)B(t)S(t, a) - \mu(a)S(t, a) - \phi(a)S(t, a)$$

$$\left(\frac{\partial}{\partial t} + \frac{\partial}{\partial a}\right) V(t, a) = \phi(a)S(t, a) - \mu(a)V(t, a) - \delta\beta(a)c(a)B(t)V(t, a)$$

$$\left(\frac{\partial}{\partial t} + \frac{\partial}{\partial a}\right) L(t, a) = \beta(a)c(a)B(t)[S(t, a) + \sigma J(t, a) + \delta V(t, a)] - [k + \mu(a)]L(t, a)$$

$$\left(\frac{\partial}{\partial t} + \frac{\partial}{\partial a}\right) I(t, a) = kL(t, a) - [r + \mu(a)]I(t, a)$$

$$\left(\frac{\partial}{\partial t} + \frac{\partial}{\partial a}\right) J(t, a) = rI(t, a) - \sigma\beta(a)c(a)B(t)J(t, a) - \mu(a)J(t, a)$$

$$B(t) = \int_0^{\infty} \frac{i(t, a')}{n(t, a')} p(t, a, a') da'$$

where

$$p(t, a, a') \geq 0, \quad \int_0^{\infty} p(t, a, a') = 1,$$

$$c(a)n(a, t)p(a, a', t) = c(a')n(a', t)p(a', a, t)$$

Ref: [1] (By E.Shim, Z. Feng, Z. Martcheva and C. Castillo-Chavez)

Reproductive Ratio (1)

- What is basic reproductive number, R_0 ?

the expected number of newly infected that one infectious individual will produce during his (or her) period of infectiousness in a large, 100% susceptible population

$$\mathfrak{R}(\phi) = \int_0^{\infty} \int_0^{\infty} \frac{k}{r-k} p_{\infty}(\tau+h) [e^{-k\tau} - e^{-r\tau}] \beta(h) c(h) [s^*(h) + \delta v^*(h)] dh d\tau$$

where

$$s^*(a) = q e^{-\int_0^a \phi(\tau) d\tau} \int_0^a d(h) e^{\int_0^h \phi(\tau) - d(\tau) d\tau} dh + (1-q) e^{-\int_0^a \phi(\tau) d\tau},$$

$$v^*(a) = \int_0^a \phi(h) s^*(h) dh,$$

Ref: [1] (By E.Shim, Z. Feng, Z. Martcheva and C. Castillo-Chavez)

Basic Reproductive Ratio (2)

Now let's consider without vaccination!

$$R_0 = \int_0^{\infty} \int_0^{\infty} \frac{k}{r-k} p_{\infty}(\tau+h) [e^{-k\tau} - e^{-r\tau}] \beta(h) c(h) [1 - q^{-dh}] dh dr$$

$$\frac{\partial R_0}{\partial q} < 0 \quad \text{and} \quad \frac{\partial R_0}{\partial(1/d_0)} < 0$$



When every new born is breast-fed ($q=1$) or when the length of mean antibody protection period increase we see reduction in basic reproductive ratio.

Ref: [1] (By E.Shim, Z. Feng, Z. Martcheva and C. Castillo-Chavez)

Local stability analysis of infection-free non-uniform steady state distributions

- Theorem 1. The infection-free steady state distribution is l.a.s. if $R(\phi) < 1$.

Proof. We introduce the characteristic equation:

$$\mathfrak{R}(\phi) = \int_0^\infty \int_0^\infty \frac{k}{r-k} p_\infty(\tau+h) [e^{-k\tau} - e^{-r\tau}] \beta(h) c(h) [s^*(h) + \delta v^*(h)] dh d\tau$$

Note that it has negative real solution of λ if and only if $G(0) < 1$ (that is, $R(\phi) < 1$) since

$$G'(\lambda) < 0, \quad \lim_{\lambda \rightarrow \infty} G(\lambda) = 0, \quad \lim_{\lambda \rightarrow -\infty} G(\lambda) = \infty.$$

Similarly it has a positive real solution λ if and only if $G(0) > 1$ (that is, $R(\phi) > 1$). Thus the infection free steady distribution is l.a.s. if $R(\phi) < 1$ and unstable otherwise.

Global stability analysis of infection-free non-uniform steady state distributions

- Theorem 2. The infection-free steady state distribution is g.a.s. if $R_0 < 1$ where

$$R_0 = \int_0^{\infty} \int_0^{\infty} \frac{k}{r-k} p_{\infty}(\tau+h) [e^{-k\tau} - e^{-r\tau}] \beta(h) c(h) [1 - q^{-dh}] dh dr$$


- Theorem 3. There exists endemic non-uniform steady state distribution if $R(\phi) > 1$.

Three doses and waning immunity?

- Keep breast-fed class: $[1-D(a)]X(a,t)$
- Susceptible class: $D(a)X(a,t)$
- Primary infection: $I(a,t)$
- Subsequent infection: $I_m(a,t)$
- Recovered class with waning immunity:
 $R_3(a,t) \rightarrow R_2(a,t) \rightarrow R_1(a,t)$
(strong)----->(weak)
- Multiple doses: $V_1(a,t) V_2(a,t) V_3(a,t)$



Model involving subsequent infection and multiple doses of vaccine.



1. Boosting immunization + natural immunity
2. Breast-fed infants: protected & non-vaccinated


Discretization on each age group

$$\begin{aligned} X_i &= \int_{a_{i-1}}^{a_i} X(a', t) da', & I_i &= \int_{a_{i-1}}^{a_i} I(a', t) da', & I_{mi} &= \int_{a_{i-1}}^{a_i} I_m(a', t) da', \\ R_{1i} &= \int_{a_{i-1}}^{a_i} R_1(a', t) da', & R_2 &= \int_{a_{i-1}}^{a_i} R_2(a', t) da', & R_{3i} &= \int_{a_{i-1}}^{a_i} R_3(a', t) da', \\ V_{1i} &= \int_{a_{i-1}}^{a_i} V_1(a', t) da', & V_{2i} &= \int_{a_{i-1}}^{a_i} V_2(a', t) da', & V_{3i} &= \int_{a_{i-1}}^{a_i} V_3(a', t) da'. \end{aligned}$$

And do normalization! i.e. divide them by the total number of individuals of age between $a_{(i-1)}$ and $a_{(i)}$

$$N_i(t) \equiv \int_{a_{i-1}}^{a_i} u(a, t) da = e^{qt} \int_{a_{i-1}}^{a_i} A(a) da := e^{qt} P_i$$



Estimation of force of infection (1)



$$\lambda_i = -\ln \left[\frac{1 - p_{i+1}}{1 - p_i} \right],$$


- p_i = proportion of individuals of age “i” who have experienced infection

Estimation of force of infection (2)




- Force of infection among younger ages are higher, especially under three years old...

Some simulated work (1)




- Primary infection incidence rates of each age group

Some simulated work (2)




- Subsequent infection incidence using base line parameters for each age group (among infants)

Immunological issues (1)



- Upon activation of B cells by antigens, B cells go through proliferating phase to make its own clones
- Finally humoral immunity results in producing short lived plasma cells (making Ab) and some B cells become memory B cells

Immunological issues (2)



- Dual effects of maternal antibodies
- **Protection:** they provide some level of protection against rotavirus infection
- **Suppressive effect:** But higher pre-vaccine Ab titers result in lower rates of sero-conversion rates after vaccination

Conclusion

- Seasonal pattern of epidemic curve
- Vaccine issues : post-birth vaccine is more efficient than neonatal vaccine.
- Local/ Global result using basic reproductive ratio
- Age-structure model: find “optimal” age window for vaccination
- Breast-feeding: longer /more breast feeding help to eradicate rotavirus infection
- Maternal antibody : its protection role and relation to immunization schedule is important.

References

- [1] E. Shim, Z. Feng, M. Martcheva and C. Castillo-Chavez. An age-structured model of rotavirus with vaccination. (submitted to JMB)
- [2] E. Shim, H.T.Banks and C. Castillo-Chavez. Seasonality of rotavirus infection with its vaccination. AMS contemporary book series. (to appear)

Future Directions



- PDE→ ODE for simulated works of three doses model.
(explore the impact of 2,4 and 6 months old schedule of Rotateq / Rotarix)
- Study Geographic pattern and find driving forces (weather, humidity, travel?)
- Impact of maternal antibodies is always important

Acknowledgement

- Dr. C. Castillo-Chavez, Dr. H.T.Banks, Dr. Z. Feng and Dr. M. Martcheva
- Arizona State University and MTBI (Mathematical and Theoretical Biology Institute)
- SAMSI and North Carolina State University